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Abstract: Celiac disease (CD), a common heritable chronic inflammatory condition of the 
small  intestine  caused  by  permanent  intolerance  to  gluten/gliadin  (prolamin),  is 
characterized  by  a  complex  interplay  between  genetic  and  environmental  factors. 
Developments in proteomics have provided an important contribution to the understanding 
of the biochemical and immunological aspects of the disease and the mechanisms involved 
in toxicity of prolamins. It has been demonstrated that some gliadin peptides resistant to 
complete proteolytic digestion may directly affect intestinal cell structure and functions by 
modulating gene expression and oxidative stress. In recent years, the creation of the two 
research  fields  Nutrigenomics  and  Nutrigenetics,  has  enabled  the  elucidation  of  some 
interactions between diet, nutrients and genes. Various dietary components including long 
chain  ω-3  fatty  acids,  plant  flavonoids,  and  carotenoids  have  been  demonstrated  to 
modulate  oxidative  stress,  gene  expression  and  production  of  inflammatory  mediators. 
Therefore their adoption could preserve intestinal barrier integrity, play a protective role 
against toxicity of gliadin peptides and have a role in nutritional therapy of celiac disease.  
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arachidonic  acid  (AA);  cycloxygenase-2  (COX-2);  cytosolic  phospholipase  A2  (cPLA2);  celiac 
disease (CD); docosahexaenoic acid (DHA); eicosapentaenoic acid (EPA); gluten free diet (GDF); 
epidermal growth factor receptor (EGFR); human leukocytes antigen (HLA); interferon-gamma (IFN-γ); 
oxidised glutathione (GSSG); reduced (GSH) glutathione; nitric oxide (NO); inducible-nitric oxide 
synthase  (iNOS);  polyunsaturated  fatty  acids  (PUFAs);  reactive  oxygen  species  (ROS);  reactive 
nitrogen species (RNS); tight junctions (TJ); tissue transglutaminase (tTG) 
1. Introduction  
Celiac disease (CD), a common heritable chronic inflammatory condition of the small intestine 
caused by permanent intolerance to gluten/gliadin (prolamin), is characterized by a complex interplay 
between genetic and environmental factors [1,2]. The prolamin fractions in cereal grains (gliadin in 
wheat and similar alcohol-soluble proteins in other cereals, secalin in rye, hordein in barley) are the 
environmental stimuli responsible for the development of intestinal damage associated with CD [2,3]. 
The classical presentation of CD as a pediatric predominant disorder, is characterized by small-intestinal 
villous atrophy and crypt hyperplasia [4,5]. However especially in adult-onset patients, a preserved 
mucosal architecture characterized by dense lymphocytic infiltration, with no villous atrophy or crypt 
hyperplasia can also be observed. 
An interplay between innate and adaptive immune responses to ingested gluten [5,6] is involved in 
CD. Developments in proteomics have provided an important contribution to the understanding of the 
biochemical and immunological aspects and the mechanisms involved in the toxicity of prolamins [7].  
It has been demonstrated that the gliadin sequence contains regions which play a special role in CD 
pathogenesis: exert a cytotoxic activity or immunomodulatory activity. Other regions trigger oxidative 
stress and induce the release of pro-inflammatory cytokines [8,9]. As a consequence, elimination of 
gluten from the diet (gluten free diet, GDF) results in a clinical improvement in CD patients.  
A previous celiac disease genome-wide association study (GWAS) demonstrated risk variants in the 
human leukocytes antigen (HLA) region [10,11]. HLA-DQ2 and HLA-DQ8 risk alleles are necessary, 
but not sufficient, for celiac disease development. Recent studies have shown that 6% of the European 
and USA population do not present these alleles [12,13]. Therefore other no-HLA risk genes need to 
be investigated.  
Several dietary components exert anti-inflammatory and antioxidant roles and have a protective 
effect on intestinal epithelium [14], therefore their adoption could contribute to preserving intestinal 
barrier integrity and play a protective role against the toxicity of gliadin peptides in CD subjects [15].  
In  recent  years,  the  creation  of  the  two  research  fields  ―Nutrigenomics‖  and  ―Nutrigenetics‖,  has 
enabled the elucidation of some interactions between diet, nutrients and genes. ―Nutrigenetics‖ refers 
to  genetically  determined  differences  in  reactivity  of  individuals  to  specific  foods,  while 
―Nutrigenomics‖ refers to the functional interactions of food with the genome. The aim of the review 
is  to  summarize  the approach  of  ―Omic‖  sciences  to  elucidate the complex  relationships  between 




2. Molecular Mechanisms on the Toxic Effects of Gluten 
Usually food proteins are degraded into small peptides and aminoacids by peptidases before they 
can be transported across the epithelium. The high proline (Pro or P) content in gliadin and similar 
proteins  of  wheat  and  related  cereals  [6],  renders  these  proteins  resistant  to  complete  proteolytic 
digestion in the human intestine. Therefore toxic oligopeptides with high concentration of proline and 
glutamine (Gln or Q) are accumulated in the small intestine and can exert toxic effects in genetically 
susceptible subjects [16].  
Figure 1. Intestinal epithelial damage in celiac disease: role of ―toxic‖ and ―immunogenic‖ 
peptides. ―Toxic‖ peptides in intestinal cells induce tight junction (TJ) dysfunctions and 
several cytotoxic effects such as apoptosis and altered cell differentiation. Most of these 
effects  are  mediated  by  increased  oxidative  stress  induced  by  gluten  peptides  in 
enterocytes.  These  alterations  reflect  in  an  impairment  of  the  epithelial  barrier  and 
increased permeability. As a consequence, both ―toxic‖ and ―immunogenic‖ peptides of 
gliadin pass through the enterocytes leading to activation of the immune response (native 
and  adaptive)  contributing  to  cell  damage  and  villous  atrophy  in  celiac  disease  (CD) 
subjects. LPMC, lamina propria mononuclear cells; tTG, Tissue transglutaminase.  
 
Different gluten peptides are involved in the CD process [8,9]. Computer modeling studies have 
demonstrated that two groups of biologically-active peptides derive from ʱ-gliadin. The serine-containing 




capacity to trigger immunological reactions in CD patients [17]. Both types of activity in celiac disease 
are possible if there is defective digestion of the active peptides. As far as concerns the serine-containing 
peptides  (Ser  or  S),  their  activity  is  linked  to  the  presence  of  PSQQ  and  QQQP  motifs.  The  
tyrosine-containing peptides (Tyr or Y), sequences such as QQPY and/or QPYP are associated with 
immunological activity and hence toxicity [7]. Some examples of peptides of ʱ-gliadin that have been 
widely investigated are P31–43, P31–49, P44–55, P57–68, P57–89, and P63–76 (Figure 1) [8].  
2.1. Imunomodulatory Effects of Gluten Peptides 
The ―immunogenic‖ peptides such as P57–68, P57–89, and P63–76 cause an adaptive response that 
proceeds through their binding to HLA-DQ2 or -DQ8 of antigen presenting cells and the subsequent 
stimulation of T-cells [18,19]  (Figure 1).  The repetitive presence of these residues  makes them a 
preferred substrate of the enzyme tissue transglutaminase (tTG), whose main function is to catalyse the 
covalent and irreversible cross-linking of a glutamine residue in glutamine-donor proteins with a lysine 
residue  in  glutamine-acceptor  proteins,  which  results  in  the  formation  of  DQ-―gluten‖  peptide 
complexes [20]. However, apart from cross-linking its substrates, tTG can also hydrolyse peptide-bound 
glutamine to glutamic acid either at a lower pH or when no acceptor proteins are available, a process 
leading to an enhanced immunogenicity of gluten peptides [1,6] (Figure 1). The DQ-―gluten‖ peptide 
complexes activate DQ2 or DQ8 restricted T-helper cells that proliferate and produce mainly Th1-type 
cytokines, particularly interferon-gamma (IFN-γ). The secretion of Th1 cytokines activates the release 
of enzymes such as matrix metalloproteinases that can damage the intestinal mucosa, with a loss of 
villous structure [21]. Th1 cytokines increase epithelial permeability which in turn will increase the 
passage of gluten peptides and peptide binding to DQ2 and DQ8 molecules on antigen-presenting 
cells, leading to a chronic feedback of the inﬂammatory process as long as gluten peptides are present 
in the intestinal lumen (Figure 1). The interactions between toxic gluten peptides and specific cells in 
lamina propria such  as epithelial cells,  macrophages and dendritic cells induce an innate immune 
response by up-regulating the expression of different mediators such as interleukin 15 (IL-15) with 
subsequent  massive  increase  of  intraepithelial  lymphocytes  [22].  These  events  contribute  to  the 
damage of the mucosal matrix [23] (Figure 1). In particular IL-15, a major mediator of the innate 
immune response is involved in proliferation of crypt enterocytes, an early alteration of CD mucosa 
causing crypts hyperplasia.  
2.2. No-Immune Mediated Cytotoxicity of Gluten: Effect on Oxidative Stress and Gene Expression 
In addition to ―immunogenic‖ effects, gliadin peptides may directly affect intestinal cell structure 
and functions as demonstrated in vitro on cultured cells and intestine biopsies [24,25]. The effects 
exerted by ―toxic peptides‖ P31–43, P31–49, P44–55 have been mainly investigated and different 
molecular mechanisms, strictly related, appear to be involved [24] (Figures 1 and 2).  
2.2.1. Effect of Gluten on Oxidative Stress  
Some  ʱ-gliadin  peptides,  in  particular  P31–43  possess  the  ability  to  penetrate  cells  [25–27]. 




leads  to  activation  of  some  signal  transduction  pathways  and  to  increased  levels  of  free  radicals 
(reactive oxygen species, ROS and reactive nitrogen species, RNS) [28] (Figures 1 and 2). Thereby it 
has been assumed that oxidative stress is one of the mechanisms that can play a role in gliadin toxicity.  
Using  different  cell  models,  it  has  been  reported  that  gliadin  exposure  reflects  in  an  intracellular 
oxidative  imbalance,  characterized  by  an  increase  in  the  levels  of  lipid  peroxidation  products  
(4-hydroxy-2(E)-nonenal (4-HNE)), an increase in the oxidised (GSSG)/reduced (GSH) glutathione 
ratio and a decrease of protein-bound sulfhydryl groups [29]. Significant structural perturbations of the 
cell  plasma  membrane  were  also  detected  [24,30].  The  increase  in  oxidative  damage  could  induce 
alterations  of  cell  morphology  [24],  cell  proliferation,  apoptosis  [31]  and  cell  viability  [32,33]. 
(Figure 1). 
Figure 2. Effect of gluten on oxidative stress and gene expression. Alteration in oxidative 
balance  induced  by  gliadin  peptides  in  enterocytes  is  involved  in  the  activation  of 
transcription factor NF-κB. NF-κB activation induces the transcription of pro-inflammatory 
cytokines and enzymes such as COX2 and iNOS with consequent higher production of 
prostaglandins  and  NO  metabolites  contributing  to  the  oxidative  stress.  The  increased 
oxidative  stress  is  also  involved  in  the  down-regulation  of  PPARγ  mediated  by  tissue 
transglutaminase  (tTG).  The  down-regulation  of  PPARγ  may  contribute  to  NF-κB 
activation. NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; COX, 
cyclooxygenase;  LOX,  lipoxygenase;  iNOS,  inducible  nitric-oxide  synthase;  PPARʴ, 
peroxisome proliferator-activated receptors gamma; ONOO•, peroxynitrite; LOOH, lipid 
hydroperoxides; •OH, hydroxyl radical; H2O2 hydrogen peroxide.  




The relationship between oxidative damage and celiac diseases is supported by several studies on 
intestinal  cells  and  circulating  cells  (Table  1).  Increased  levels  of  prostaglandin  E2  (PGE2)  were 
demonstrated  in  homogenized  small  bowel  biopsy  specimens  from  patients  with  active  celiac  
disease [34] while the levels of the antioxidant enzyme glutathione peroxidase and reductase were 
decreased in biopsies from celiac disease patients with consequent decreased levels of GSH [35–37] 
(Table 1). Several investigations reported that reactive nitrogen species such as nitric oxide (NO) also 
play an important role in the pathogenesis of celiac disease with enhanced NO. Inducible-nitric oxide 
synthase (iNOS) is constitutively expressed in human duodenal enterocytes; its activity is increased in 
patients with untreated celiac disease [38–40] and is partially corrected when patients are treated with 
GFD [41,42]. High levels of NO are present in serum [43–47] and urine [48–50] of children with 
celiac disease and correlate with an increased expression of iNOS in the small intestine (Table 1).  
Table 1. Alterations in the levels of markers of oxidative stress and of antioxidant enzymes 




↑ level of lipid hydroperoxides (LOOH)  
↓ reduced glutathione (GSH) levels  
↓ glutathione peroxidase (GPx) activity  
↓ glutathione reductase (GR) activity  
↑ superoxide dismutase (SOD) activity  
↓ paraoxonase-1 (PON1) and paraoxonase-3 (PON3) expression  
↑ inducible-nitric oxide synthase (iNOS) expression  
Blood (plasma 
and blood cells) 
↑ lipid hydroperoxides (LOOH) level in plasma  
↑ thiobarbituric acid-reactive substances levels in plasma and lipoproteins  
↑ carbonyl groups levels in plasma  
↑ 8-hydroxyguanosine (8-oxodG) in DNA in leukocytes  
↑ NO metabolite levels plasma  
↑ nitrotyrosine levels in plasma  
↓ reduced glutathione levels in plasma  
↑ blood superoxide dismutase (SOD) activity  
↓ blood glutathione peroxidase (GPx) activity  
↓ blood glutathione reductase (GR) activity  
↓ alpha-tocopherol levels in plasma and in erythrocytes  
↓ plasma ascorbic acid levels  
↓ plasma retinol levels  
Urine  ↑ 8-hydroxyguanosine (8-oxodG) in DNA metabolite levels  
An increase of markers of oxidative damage of lipids (thiobarbituric acid-reactive substances and 
lipid hydroperoxides), proteins (carbonyl groups) and DNA was demonstrated in intestinal cells and 
biological  fluids  [51–54]  of  CD  with  respect  to  controls  (Table  1).  Changes  in  vitamin  E  and 
antioxidant enzyme activities were observed also in circulating cells and plasma of patients [49–55] 
(Table 1). A decreased expression of the antioxidant and anti-inflammatory enzymes PON1 and PON3 
mRNA  was  reported  by  Rothem  et  al.  in  intestinal  biopsy  of  celiac  patients  [56].  The  decreased 
antioxidant defenses may compromise the inflamed mucosa, rendering it more susceptible to oxidative 




2.2.2. Effect of Gluten on Gene Expression: Relationship with Oxidative Stress and Inflammation  
Several studies have demonstrated that gliadin peptides are able to modulate gene expression in 
several cellular models [57,58]. The increased levels of ROS is involved in the reduced degradation of 
tTG by the ubiquitine-proteasome system, thus leading to increased tTG protein levels in susceptible 
targets as coeliac mucosa. An uncontrolled activation of the ROS-tTG axis induced by P31–43 leads to 
down-regulation of PPARγ with a derangement of the appropriate control of inflammation [59,60] 
(Figure  2).  A  down-regulation  of  PPARγ  in  CD  subjects  is  confirmed  by  proteomic  analysis  of 
duodenal biopsies from celiac subjects [61]. In fact PPARγ receptor produced by several cell types, 
including  epithelial  cells,  negatively  regulates  inflammatory  gene  expression  by  ―transrepressing‖ 
inflammatory responses and even by modulating oxidative stress [28,59]. The increased secretion of 
inflammatory cytokines may, in turn, derange intestinal permeability and enhance the toxic effects of 
environmental triggers [57]. It has been hypothesized that the down-regulation of PPARγ may also 
contribute to NF-κB activation (Figure 2). In celiac disease, pro-inflammatory cytokines, adhesion 
molecules,  and  enzymes  whose  gene  expression  is  known  to  be  regulated  by  NF-κB  are  
involved [57,62]. The synthesis of NF-κB and other transcription factors is dependent also on the 
intracellular redox state [63] and can promote synergistically transcriptional activity of pro-inflammatory 
genes [64]. In fact an increased expression of cycloxygenase-2 (COX-2), cytosolic phospholipase A2 
(cPLA2) activity and IL-8 release in culture medium have been observed in cells incubated in the 
presence of gliadin peptides [58,65]. Moreover, in IFN-γ-stimulated RAW 264.7 macrophages, gliadin 
increases iNOS gene expression through a mechanism involving NF-κB and other transcription factors 
(IRF-1 and STAT-1ʱ) [57,66] (Figure 2). An increased expression of several cytokines was observed 
in the epithelium of patients with active celiac disease [67,68]. Moreover, as aforementioned, patients 
with active CD and those on a gluten free diet have significantly higher levels of proinflammatory 
cytokines in the plasma, such as INF-γ, interleukin (IL)-1β, tumor necrosis factor-ʱ (TNF-ʱ), IL-6 and 
IL-8 compared to no celiac subjects [69]. 
The association between gluten, oxidative stress, gene expression and inflammation is supported by 
recent studies. The analysis of gene expression in small-bowel mucosal biopsy samples from untreated 
celiac disease patients using cDNA microarray has shown that about nine of 30 genes involved in cell 
signaling  and  differentiation  were  modified  (receptor  tyrosine  kinase  pathway  starting  from  the 
epithelial  growth  factor  receptor)  with  respect  to  control  samples  [70].  Using  a  three-dimensional 
epithelial cell differentiation model, it has been demonstrated that expression of about 29 genes is 
modified following the reaction to gluten. It has to be stressed that nine affected genes are involved 
directly or indirectly in the intracellular epidermal growth factor receptor (EGFR) signaling pathway. 
Therefore it has been hypothesized that a peptic tryptic digest of gluten and small gluten peptides 
elicits EGF-like responses on epithelial cells [71]. Removal of gluten from the ingested diet resulted in 
reversion in the transcription of 29 of 30 genes in the small-bowel biopsy samples.  
3. Nutritional Genomics in Celiac Disease  
Various  dietary  components  including  plant  polyphenols,  carotenoids  and  fatty  acids,  have  the 




in nutritional therapy of celiac disease [14,72]. These components act through a variety of mechanisms 
including decreasing inflammatory mediator production through effects on cell signalling and gene 
expression, reducing the production of damaging oxidants and promoting gut barrier function and  
anti-inflammatory responses (Figure 3).  
Figure 3. Protective effect of phytonutrients on cytotoxicity of gluten peptides. Antioxidant 
vitamins (vitamin C and E), polyphenols and carotenoids from dietary vegetable food and 
oil, were absorbed by intestinal cells and could exert protective effects against toxic effects 
exerted by gluten peptides on intestinal cells.  
 
3.1. Antioxidant Vitamins  
Vitamin C and E are able to modulate immune responses in several ways, for instance by modulating 
leukocyte function and lymphocyte proliferation [73]. Vitamin C and E exert also antioxidant activity, 
and thereby modulate the inflammatory process. A decreased NF-κB activation with a consequent 
decreased  release  of  pro-inflammatory  cytokines  (IL-8  and  PAI-1)  in  the  presence  of  vitamin  E 
(particularly γ-tocopherol) has also been shown [74]. 
Bernardo  et  al.  (2011)  have  recently  reported  that  administration  of  vitamin  C  in  small-bowel 
mucosal biopsy organ culture system prevents the augmented secretion IFN-γ, TNF-ʱ, and IL-6 and 
increases the expression of IL-15 triggered by gliadin, suggesting that vitamin C supplementation 
might be beneficial for celiac patients [75]. 
3.2. Phyochemicals: Polyphenols and Carotenoids  
Fruit and vegetables contain several polyphenols and carotenoids that produce distinct biological 




anti-inflammatory properties. A likely target for these compounds seems to be the signal transduction 
cascade leading to the activation of transcription factors such as NF-κB [76–78]. Flavonoids have  
anti-inflammatory  activity  through  several  action  mechanisms  involving  the  reduction  in  the 
concentration of prostanoids and leukotrienes through the inhibition of eicosanoid generating enzymes 
such as phospholipase A2, COX and LOX and the inhibition of iNOS induction and expression in 
different cell models [14,78]. Also carotenoids are able to inhibit the expression of inflammation-related 
enzymes/proteins  partly  by  suppressing  activation  of  NF-κB,  an  effect  potentially  mediated  by  
the  inhibition  of  different  protein  kinases  (e.g.,  mitogen-activated  protein  kinase;  extracellular  
signal-regulated kinase) involved in signal transduction pathway [13,77].  
Other authors have reported that lycopene, quercetin, and tyrosol decrease iNOS and COX-2 gene 
expression induced by gliadin in RAW 264.7 macrophages stimulated with IFN-γ [79]. The inhibition 
of iNOS and COX-2 gene expression occurred at transcriptional level by preventing NF-κB, IRF-1 and 
STAT-1ʱ  activation  and  was  correlated  with  the  inhibition  of  reactive  oxygen  species  generation 
induced by gliadin and IFN-γ [79]. 
Flavonoids  such  as  epigallocatechin  gallate,  genistein,  myricetin  and  quercetin  have  also  a 
protective effect on intestinal TJ barrier function [80]. As aforementioned, the TJs have crucial roles in 
paracellular  transport  of  gluten  as  well  as  in  barrier  function  in  the  intestines.  As  reviewed  by  
Suzuki et al. (2011), flavonoids ameliorate intestinal TJ barrier dysfunction induced by oxidative stress 
and  by inflammatory  cytokines  [80]. Quercetin has  been reported to enhance intestinal TJ barrier 
function through the assembly and expression of TJ proteins. The change in phosphorylation status is 
responsible for the quercetin-mediated assembly of TJ proteins [80].  
3.3. Fatty Acids 
Fatty acids can influence inflammation through a variety of mechanisms, including acting via cell 
surface and intracellular receptors/sensors that control inflammatory cell signaling and gene expression 
patterns  [72].  Eicosanoids  produced  from  n-6  fatty  acids  such  as  arachidonic  acid  (AA)  have  a  
pro-inflammatory role. Conversely, n-3 fatty acids such as eicosapentaenoic acid (EPA) gives rise to 
eicosanoids  with  anti-inflammatory  properties  [72].  An  excellent  example  of  nutrigenomics  is  the 
influence of n-3 fatty acids on gene expression. In particular n-3 fatty acids have been reported to 
inhibit the activation of the transcription factor NF-κB with consequent inhibition of pro-inflammatory 
cytokine production.; in contrast, saturated fatty acids, especially lauric acid (12:0), enhanced NF-κB 
activation in macrophages and dendritic cells [81]. 
The effect of fatty acids on gene expression could be mediated also via fatty acid sensors or receptors 
such as PPARγ. In fact polyunsaturated fatty acids (PUFAs) and their derivatives are endogenous 
ligands for PPAR-γ and it has been demonstrated that PUFA-induced PPAR-γ is associated with a 
reduction in production of pro-inflammatory cytokines (TNF-ʱ and IL-6) [82]. 
As far as concerns celiac disease it has been demonstrated that the cytosolic phospholipase A2 
(cPLA2)—dependent  release  of  AA  from  the  intra-epithelial  lymphocytes  after  incubation  with 
gliadin, contribute to lymphocytes cytolysis and to the immune response of celiac disease. Moreover, 
using  a  human  intestinal  epithelial  cell  line  (Caco-2)  exposed  to  gliadin  peptides,  it  has  been 




proinflammatory effects of AA. In fact DHA prevented the AA release, cycloxygenase-2 expression, 
cPLA2 activity and prostaglandin E2 and interleukin-8 release in culture medium suggesting that DHA 
inhibits the AA release by these cells [83].  
4. Conclusions  
Celiac disease is characterized by a complex interaction between genetic and environmental factors. 
The mucosal damage in celiac patients is considered to be induced by an interplay between innate and 
adaptive immune responses to ingested gluten. Developments in proteomics have provided an important 
contribution to the understanding of the biochemical and immunological aspects and the mechanisms 
involved in toxicity of prolamins. Inflammation and oxidative stress due to an increase of reactive 
oxygen species and a decrease of antioxidant defenses are involved in the molecular mechanisms of 
celiac  disease.  This in  turn leads to uncontrolled activation of the  redox-sensitive, pro-inflammatory 
transcription factors NF-κB, continued production of ROS and RNS and support of chronic inflammation.  
Previous studies have demonstrated that several nutrients exert antioxidant effects and influence 
gene expression, therefore they represent a useful approach for nutritional intervention in CD subjects, 
as  corroborated  by  recent  in  vitro  studies  that  have  demonstrated  that  phytonutrients  (lycopene, 
quercitine, vitamin C and tyrosol) protect against the cytotoxic effect of gliadin. A protective effect has 
also been exerted by DHA.  
To realize the usefulness of nutritional genomics as a tool for targeted medical nutrition therapy, 
further basic research, extensive epidemiological studies and controlled intervention trials are needed 
to investigate whether long chain unsaturated fatty acids , antioxidant vitamins , plant polyphenols and 
carotenoids modulate in vivo predisposition of chronic inflammatory conditions and thus have a role in 
the therapy of celiac disease.  
Conflict of Interest 
The authors declare no conflict of interest.  
References  
1.  Sollid, L.M.; Jabri, B. Is celiac disease an autoimmune disorder? Curr. Opin. Immunol. 2005, 17, 
595–600.  
2.  Van Heel, D.A.; West, J. Recent advances in coeliac disease. Gut 2006, 36, 864–874. 
3.  Wieser, H.; Koehler, P. The biochemical basis of celiac disease. Cereal Chem. 2008, 85, 1–13. 
4.  Diosdado, B.; van Oort, E.; Wijmenga, C. ―Coelionomics‖: Towards understanding the molecular 
pathology of coeliac disease. Clin. Chem. Lab. Med. 2005, 43, 685–695.  
5.  Koning, F.; Schuppan, D.; Cerf-Bensussan, N.; Sollid, L.M. Pathomechanisms in celiac disease. 
Best Pract. Res. Clin. Gastroenterol. 2005, 19, 373–387.  
6.  Jabri, B.; Kasarda, D.D.; Green, P.H.R. Innate and adaptive immunity: The Yin and Yang of 
celiac disease. Immunol. Rev. 2005, 206, 219–231. 
7.  Mamone, G.; Picarello, G.; Addeo, F.; Ferranti, P. Proteomic analysis in allergy and intolerance to 




8.  Ciccocioppo, R.; di Sabatino, A.; Corazza, G.R. The immune recognition of gluten in coeliac 
disease. Clin. Exp. Immunol. 2005, 140, 408–416. 
9.  Shan, L.; Molberg, Ø.; Parrot, I.; Hausch, F.; Filiz, F.; Gray, G.M.; Sollid, L.M.; Khosla, C. 
Structural basis for gluten intolerance in celiac sprue. Science 2002, 297, 2275–2279. 
10.  Trynka, G.; Zhernakova, A.; Romanos, J.; Franke, L.; Hunt, K.A.; Turner, G.; Bruinenberg, M.; 
Heap, G.A.; Platteel, M.; Ryan, A.W.; et al. Coeliac disease-associated risk variants in TNFAIP3 
and REL implicate altered NF-kappaB signalling. Gut 2009, 58, 1078–1083. 
11.  Vader,  W.;  Stepniak,  D.;  Kooy,  Y.;  Mearin,  L.;  Thompson,  A.;  van  Rood,  J.J.;  Spaenij,  L.; 
Koning,  F.  The  HLA-DQ2  gene  dose  effect  in  celiac  disease  is  directly  related  to  the  
magnitude and breadth of gluten-specific T cell responses. Proc. Natl. Acad. Sci. USA 2003, 100, 
12390–12395. 
12.  Harmon,  G.S.;  Lebeck,  L.K.;  Weidner,  N.  Gluten-dependent  enteropathy  and  atypical  human 
leukocyte antigen alleles. Hum. Pathol. 2011, 42, 1112–1126.  
13.  Karell, K.; Louka, A.S.; Moodie, S.J.; Ascher, H.; Clot, F.; Greco, L.; Ciclitira, P.J.; Sollid, L.M.; 
Partanen, J. European genetics cluster on celiac disease. Hum. Immunol. 2003, 64, 469–477. 
14.  Calder, P.C.; Albers, R.; Antoine, J.M.; Blum, S.; Bourdet-Sicard, R.; Ferns, G.A.; Folkerts, G.; 
Friedmann, P.S.; Frost, G.S.; Guarner, F.; et al. Inflammatory disease processes and interactions 
with nutrition. Br. J. Nutr. 2009, 101, 1–45. 
15.  Matysiak-Budnik, T.; Candalh, C.; Dugave, C.; Namane, A.; Cellier, C.; Cerf-Bensussan, N.; 
Heyman, M. Alterations of the intestinal tran sport and processing of gliadin peptides in celiac 
disease. Gastroenterology 2003, 125, 696–707. 
16.  Trynka, G.; Wijmenga, C.; van Heel, D.A. A genetic perspective on coeliac disease. Trends Mol. 
Med. 2010, 16, 537–550. 
17.  Cornell, H.J.; Wills-Johnson, G. Structure-activity relationships in coeliac-toxic gliadin peptides. 
Amino Acid 2001, 21, 243–253.  
18.  Auricchio, S.; Barone, M.V.; Troncone, R. Dietary proteins and mechanismsof gastrointestinal 
diseases: Gliadin as a model. J. Pediatr. Gastroenterol. Nutr. 2004, 39, S738–S739. 
19.  Hausch, F.; Shan, L.; Santiago, N.A.; Gray, G.M.; Khosla, C. Intestinal digestive resistance of 
immunodominant gliadin peptides. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283, 996–1003. 
20.  Folk, J.E. Mechanism and basis for specificity of transglutaminasecatalyzede-(g-glutamyl) lysine 
bond formation. Adv. Enzymol. Relat. Areas Mol. Biol. 1983, 54, 1–56. 
21.  Kagnoff, M.F. Overview and pathogenesis of celiac disease. Gastroenterology 2005, 128, 10–18. 
22.  Maiuri, L.; Ciacci, C.; Ricciardelli, I.; Vacca, L.; Raia, V.; Auricchio, S.; Picard, J.; Osman, M.; 
Quarantino,  S.;  Londei,  M.  Association  between  innate  response  to  gliadin  and  activation  of 
pathogenic T cells in celiac disease. Lancet 2003, 362, 30–37. 
23.  Pender, S.L.F.; Lionetti, P.; Murch, S.H.; Wathan, N.; MacDonald, T.T. Proteolytic degradation 
of intestinal mucosa extracellular matrix after lamina propria T cell activation.  Gut 1996, 39,  
284–290. 
24.  Elli, L.; Dolfini, E.; Bardella, M.T. Gliadin cytotoxicity and in vitro cell cultures. Toxicol. Lett. 




25.  Maiuri, L.; Troncone, R.; Mayer, M.; Coletta, S.; Picarelli, A.; de Vincenzi, M.; Pavone, V.; 
Auricchio, S. In vitro activities of A-gliadin related synthetic peptides: Damaging affect on the 
atrophic  coeliac  mucosa  and  activation  of  mucosal  immune  response  in  the  treated  coeliac 
mucosa. Scand. J. Gastroenterol. 1996, 31, 247–253. 
26.  Schumann, M.; Richter, J.F.; Wedell, I.; Moos, V.; Zimmermann-Kordmann, M.; Schneider, T.; 
Daum, S.; Zeitz, M.; Fromm, M.; Schulzke, J.D. Mechanisms of epithelial translocation of the  
a2-gliadin-33mer in coeliac sprue. Gut 2008, 57, 747–754. 
27.  Heyman, M.; Menard, S. Pathways of gliadin transport in celiac disease. Ann. N. Y. Acad. Sci. 
2009, 1165, 274–278.  
28.  Zimmer, K.P.; Fischer, I.; Mothes, T.; Weissen-Plenz, G.; Schmitz, M.; Wieser, H.; Bü ning, J.; 
Lerch, M.M.; Ciclitira, P.C.; Weber, P.; et al. Endocytotic segregation of gliadin peptide 31–49 in 
enterocytes. Gut 2010, 59, 300–310. 
29.  Luciani,  A.;  Villella,  V.R.;  Vasaturo,  A.;  Giardino,  I.;  Pettoello-Mantovani,  M.;  Guido,  S.;  
Cexus, O.N.; Peake, N.; Londei, M.; Quaratino, S.; et al. Lysosomal accumulation of gliadin  
p31–43  peptide  induces  oxidative  stress  and  tissue  transglutaminase-mediated  PPARgamma 
downregulation in intestinal epithelial cells and coeliac mucosa. Gut 2010, 59, 311–319.  
30.  Rivabene, R.; Mancini, E.; de Vincenzi, M. In vitro cytotoxic effect of wheat gliadin-derived 
peptides on the Caco-2 intestinal cell line is associated with intracellular oxidative imbalance: 
Implications for coeliac disease. Biochim. Biophys. Acta 1999, 1453, 152–160. 
31.  Di  Sabatino,  A.;  Ciccocioppo,  R.;  D’Alò,  S.;  Parroni,  R.;  Millimaggi,  M.;  Cifone,  M.G.;  
Corazza, G.R. Intraepithelial and lamina propria lymphocytes show distinct patterns of apoptosis 
whereas both populations are active in Fas based cytotoxicity in coeliac disease. Gut 2001, 49, 
380–386. 
32.  Giovannini, C.; Sanchez, M.; Straface, E.; Scazzocchio, B.; Silano, M.; de Vincenzi, M. Induction 
of apoptosis in CaCo-2 cells by wheat gliadin peptides. Toxicology 2000, 145, 63–71. 
33.  Giovannini, C.; Mancini, E.; de Vincenzi, M. Inhibition of the cellular metabolism of Caco-2 cells 
by prolamin peptides from cereals toxic for coeliacs. Toxicol. In Vitro 1996, 10, 533–538.  
34.  Giovannini, C.; Maiuri, L.; de Vincenzi, M.; Cytotoxic effect of prolamin-derived peptides on  
in vitro cultures of cell line Caco-2: Implications for coeliac disease. Toxicol. In Vitro 1994, 9,  
251–255. 
35.  Dolfini, E.; Elli, L.; Dasdia, T.; Bufardeci, B.; Colleoni, M.P.; Costa, B.; Floriani, I.; Falini, M.L.; 
Guerrieri, N.; Forlani, F.; et al. In vitro cytotoxic effect of bread wheat gliadin on the LoVo 
human adenocarcinoma cell line. Toxicol. In Vitro 2002, 16, 331–337. 
36.  Lavö , B.; Knutson, L.; Lö ö f, L.; Hä llgren, R. Gliadin challenge-induced jejunal prostaglandin E2 
secretion in celiac disease. Gastroenterologist 1990, 99, 703–709. 
37.  Stojiljković, V.; Todorović, A.; Pejić, S.; Kasapović, J.; Saicić, Z.S.; Radlović, N.; Pajović, S.B. 
Antioxidant status and lipid peroxidation in small intestinal mucosa of children with celiac disease. 
Clin. Biochem. 2009, 42, 1431–1437. 
38.  Stahlberg, M.R.; Hietanen, E.; Maki, M. Mucosal biotransformation rates in the small intestine of 
children. Gut 1988, 29, 1058–1063. 
39.  Sido, B.; Hack, V.; Hochlehnert, A.; Lipps, H.; Herfarth, C.; Droge, W. Impairment of intestinal 




40.  Daniels, I.; Cavill, D.; Murray, I.A.; Long, R.G. Elevated expression of iNOS mRNA and protein 
in coeliac disease. Clin. Chim. Acta 2005, 356, 134–142. 
41.  Ter Steege, J.; Buurman, W.; Arends, J.W.; Forget, P. Presence of inducible nitric oxide synthase, 
nitrotyrosine, CD68, and CD14 in the small intestine in celiac disease. Lab. Invest. 1997, 77,  
29–36. 
42.  Beckett,  C.G.;  Dell’Olio,  D.;  Ellis,  H.J.;  Rosen-Bronson,  S.;  Ciclitira,  P.J.  The  detection  and 
localization of inducible nitric oxide synthase production in the small intestine of patients with 
coeliac disease. Eur. J. Gastroenterol. Hepatol. 1998, 10, 641–647. 
43.  Holmgren Peterson, K.; Falth-Magnusson, K.; Magnusson, K.E.; Stenhammar, L.; Sundqvist, T. 
Children with celiac disease express inducible nitric oxide synthase in the small intestine during 
gluten challenge. Scand. J. Gastroenterol. 1998, 33, 939–943. 
44.  Murray, I.A.; Daniels, I.; Coupland, K; Smith, J.A.; Long, R.G. Increased activity and expression 
of  iNOS  in  human  duodenal  enterocytes  from  patients  with  celiac  disease.  Am.  J.  Physiol. 
Gastrointest. Liver Physiol. 2002, 283, 319–326. 
45.  Murray,  I.A.;  Bullimore,  D.W.;  Long,  R.G.  Fasting  plasma  nitric  oxide  products  in  coeliac 
disease. Eur. J. Gastroenterol. Hepatol. 2003, 15, 1091–1095. 
46.  Ter  Steege,  J.C.;  Koster-Kamphuis,  L.;  van  Straaten,  E.A.;  Forget,  P.P.;  Buurman,  W.A. 
Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free 
Radic. Biol. Med. 1998, 25, 953–963. 
47.  Ertekin, V.; Selimoğlu, M.A.; Türkan, Y.; Akçay, F. Serum nitric oxide levels in children with 
celiac disease. J. Clin. Gastroenterol. 2005, 39, 782–785. 
48.  Van  Straaten,  E.A.;  Koster-Kamphuis,  L.;  Bovee-Oudenhoven,  I.M.;  van  der  Meer,  R.;  
Forget,  P.P.  Increased  urinary  nitric  oxide  oxidation  products  in  children  with  active  coeliac 
disease. Acta Paediatr. 1999, 88, 528–531.  
49.  Hö gberg, L.; Webb, C.; Fä lth-Magnusson, K.; Forslund, T.; Magnusson, K.E.; Danielsson, L.; 
Ivarsson, A.; Sandströ m, O.; Sundqvist, T. Children with screening-detected coeliac disease show 
increased levels of nitric oxide products in urine. Acta Paediatr. 2011, 100, 1023–1027. 
50.  Sundqvist, T.; Laurin, P.; Fä lth-Magnusson, K.; Magnusson, K.E.; Stenhammar, L. Significantly 
increased  levels  of  nitric  oxide  products  in  urine  of  children  with  celiac  disease.  J.  Pediatr. 
Gastroenterol. Nutr. 1998, 27, 196–198. 
51.  Stojiljković,  V.;  Todorović,  A.;  Radlović,  N.;  Pejić,  S.;  Mladenović,  M.;  Kasapović,  J.;  
Pajović,  S.B.  Antioxidant  enzymes,  glutathione  and  lipid  peroxidation  in  peripheral  blood  of 
children affected by coeliac disease. Ann. Clin. Biochem. 2007, 44, 537–543. 
52.  Odetti,  P.;  Valentini,  S.;  Aragno,  I.;  Garibaldi,  S.;  Pronzato,  M.A.;  Rolandi,  E.;  Barreca,  T. 
Oxidative stress in subjects affected by celiac disease. Free Radic. Res. 1998, 29, 7–24. 
53.  Lavy, A.; Ben Amotz, A.; Aviram, M. Increased susceptibility to undergo lipid peroxidation of 
chylomicrons and low-density lipoprotein in celiac disease. Ann. Nutr. Metab. 1993, 37, 68–74. 
54.  Szaflarska-Poplawska, A.; Siomek, A.; Czerwionka-Szaflarska, M.; Gackowski, D.; Ró zalski, R.; 
Guz, J.; Szpila, A.; Zarakowska, E.; Olinski, R. Oxidatively damaged DNA/oxidative stress in 
children with celiac disease. Cancer Epidemiol. Biomark. Prev. 2010, 19, 1960–1965. 
55.  Hozyasz, K.K.; Chelchowska, M.; Laskowska-Klita, T. Vitamin E levels in patients with celiac 




56.  Rothem,  L.;  Hartman,  C.;  Dahan,  A.;  Lachter,  J.;  Eliakim,  R.;  Shamir,  R.  Paraoxonases  are 
associated with intestinal inflammatory diseases and intracellularly localized to the endoplasmic 
reticulum. Free Radic. Biol. Med. 2007, 43, 730–739. 
57.  Maiuri, M.C.; de Stefano, D.; Mele, G.; Iovine, B.; Bevilacqua, M.A.; Greco, L.; Auricchio, S.; 
Carnuccio, R. Gliadin increases iNOS gene expression in interferon—Stimulated RAW 264.7 
cells through a mechanism involving NF-κB. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 
368, 63–71. 
58.  de Stefano, D.; Maiuri, M.C.; Iovine, B.; Ialenti, A.; Bevilacqua, M.A.; Carnuccio, R. The role of 
NF-κB, IRF-1, and STAT-1ʱ transcription factors in the iNOS gene induction by gliadin and  
IFN-γ in RAW 264.7 macrophages. J. Mol. Med. 2006, 84, 65–74. 
59.  Thomas, K.E.; Sapone, A.; Fasano, A.; Vogel, S.N. Gliadin stimulation of murine macrophage 
inflammatory  gene  expression  and  intestinal  permeability  are  MyD88-dependent:  Role  of  the 
innate immune response in celiac disease. J. Immunol. 2006, 176, 2512–2521. 
60.  Maiuri, L.; Ciacci, C.; Ricciardelli, I.; Vacca, L.; Raia, V.; Rispo, A.; Griffin, M.; Issekutz, T.; 
Quaratino, S.; Londei, M. Unexpected role of surface transglutaminase type II in celiac disease. 
Gastroenterology 2005, 129, 1400–1413. 
61.  Luciani,  A.;  Villella,  V.R.;  Vasaturo,  A.;  Giardino,  I.;  Pettoello-Mantovani,  M.;  Guido,  S.;  
Cexus, O.N.; Peake, N.; Londei, M.; Quaratino, S.; et al. Lysosomal accumulation of gliadin 
p31e43  peptide  induces  oxidative  stress  and  tissue  transglutaminase-mediated  PPARg 
downregulation in intestinal epithelial cells and coeliac mucosa. Gut 2010, 59, 311–319. 
62.  de Re, V.; Simula, M.P.; Notarpietro, A.; Canzonieri, V.; Cannizzaro, R.; Toffoli, G. Do gliadin 
and  tissue  transglutaminase  mediate  PPAR  downregulation  in  intestinal  cells  of  patients  with 
coeliac disease? Gut 2010, 59, 1730–1731. 
63.  Simula, M.P.; Cannizzaro, R.; Canzonieri, V.; Pavan, A.; Maiero, S.; Toffoli, G.; de Re, V. PPAR 
signaling  pathway  and  cancer-related  proteins  are  involved  in  celiac  disease-associated  tissue 
damage. Mol. Med. 2010, 16, 199–209. 
64.  Maiuri, M.C.; de Stefano, D.; Mele, G.; Fecarotta, S.; Greco, L.; Troncone, R.; Carnuccio, R. 
Nuclear factor kappa B is activated in small intestinal mucosa of celiac patients. J. Mol. Med. 
2003, 81, 373–379.  
65.  Flohè , L.; Brigelius-Flohe, R.; Saliou, C.; Traber, M.G.; Packer, L. Redox regulation of NF-κB 
activation. Free Radic. Biol. Med. 1997, 22, 1115–1126. 
66.  Ohmori, Y.; Hamilton, T.A. Cooperative interaction between interferon (IFN) stimulus response 
element and kappa B sequence motifs controls IFN gamma- and lipopolysaccharide-stimulated 
transcription from the murine IP 10 promoter. J. Biol. Chem. 1993, 268, 6677–6688. 
67.  Vincentini,  O.;  Quaranta,  M.G.;  Viora,  M.;  Agostoni,  C.;  Silano,  M.  Docosahexaenoic  acid 
modulates in vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition 
of cPLA2. Clin. Nutr. 2011, 30, 541–546. 
68.  Friis,  S.;  Anthonsen,  D.;  Noré n,  O.;  Sjö strö m,  H.  Gamma-type  gliadins  cause  secretion  of 
prostaglandin E2 in patients with coeliac disease. Clin. Chim. Acta 1994, 231, 173–183. 
69.  Juuti-Uusitalo, K.; Mä ki, M.; Kaukinen, K.; Collin, P.; Visakorpi, T.; Vihinen, M.; Kainulainen, H. 
cDNA  microarray  analysis  of  gene  expression  in  coeliac  disease  jejunal  biopsy  samples.  




70.  Juuti-Uusitalo, K.; Mä ki, M.; Kainulainen, H.; Isola, J.; Kaukinen, K. Gluten affects epithelial 
differentiation-associated genes in small intestinal mucosa of coeliac patients. Clin. Exp. Immunol. 
2007, 150, 294–305.  
71.  Cataldo, F.; Lio, D.; Marino, V.; Scola, L.; Crivello, A.; Corazza, G.R.; Working Group of the 
SIGEP; Working Group of ―Club del Tenue‖. Plasma cytokine profiles in patients with celiac 
disease and selective IgA deficiency. Pediatr. Allergy Immunol. 2003, 14, 320–324. 
72.  Calder, P.C. Fatty acids and inflammation: The cutting edge between food and pharma. Eur. J. 
Pharmacol. 2011, 668, 50–58. 
73.  Goetzl,  E.J.;  Wasserman,  S.I.;  Gigli,  I.;  Austen,  K.F.  Enhancement  of  random  migration  and 
chemotactic response of human leukocytes by ascorbic acid. J. Clin. Invest. 1974, 53, 813–818. 
74.  Cook-Mills,  J.M.;  McCary,  C.A.  Isoforms  of  vitamin  E  differentially  regulate  inflammation. 
Endocr. Metab. Immune Disord. Drug Targets 2010, 10, 348–366. 
75.  Bernardo,  D.;  Martí nez-Abad,  B.;  Vallejo-Diez,  S.;  Montalvillo,  E.;  Benito,  V.;  Anta,  B.; 
Ferná ndez-Salazar,  L.;  Blanco-Quiró s,  A.;  Garrote,  J.A.;  Arranz,  E.  Ascorbate-dependent 
decrease of the mucosal immune inflammatory response to gliadin in coeliac disease patients. 
Allergol. Immunopathol. 2012, 40, 3–8. 
76.  Hecker, M.; Preiss, C.; Klemm, V.; Busse, R. Inhibition by antioxidants of nitric oxide synthase 
expression  in  murine  macrophages:  Role  of  nuclear  factor  kappa  B  and  interferon  regulatory 
factor 1. Br. J. Pharmacol. 1996, 118, 2178–2184. 
77.  Heber, D.; Lu, Q.Y. Overview of mechanisms of action of lycopene. Exp. Biol. Med. 2002, 227, 
920–923. 
78.  Di Carlo, G.; Mascolo, N.; Izzo, A.A.; Capasso, F. Flavonoids: Old and new aspects of a class of 
natural therapeutic drugs. Life Sci. 1999, 65, 337–353. 
79.  de Stefano, D.; Maiuri, M.C.; Simeon, V.; Grassia, G.; Soscia, A.; Cinelli, M.P.; Carnuccio, R. 
Lycopene,  quercetin  and  tyrosol  prevent  macrophage  activation  induced  by  gliadin  and  
IFN-gamma. Eur. J. Pharmacol. 2007, 566, 192–199.  
80.  Suzuki, T.; Hara, H. Role of flavonoids in intestinal tight junction regulation. J. Nutr. Biochem. 
2011, 22, 401–408.  
81.  Lee, J.Y.; Sohn, K.H.; Rhee, S.H.; Hwang, D. Saturated fatty acids, but not unsaturated fatty acids, 
induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 
2001, 276, 16683–16689. 
82.  Zapata-Gonzalez,  F.;  Rueda,  F.;  Petriz,  J.;  Domingo,  P.;  Villarroya,  F.;  Diaz-Delfin,  J.;  
de Madariaga, M.A.; Domingo, J.C. Human dendritic cell activities are modulated by the omega-3 
fatty acid, docosahexaenoic acid, mainly through PPAR(gamma):RXR heterodimers: Comparison 
with other polyunsaturated fatty acids. J. Leukoc. Biol. 2008, 84, 1172–1182.  
83.  Vincentini,  O.;  Quaranta,  M.G.;  Viora,  M.;  Agostoni,  C.;  Silano,  M.  Docosahexaenoic  acid 
modulates in vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition 
of cPLA2. Clin. Nutr. 2011, 30, 541–546.  
©  2012  by  the authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 